Friday, February 27, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Politics & Law

Paths of Understanding

Daily Remedy by Daily Remedy
August 8, 2021
in Politics & Law
0

Starting in 2020, the Centers for Disease Control and Prevention (CDC) began soliciting comments from the general public as to how it should revise the 2016 opioid prescribing guidelines.

To date the CDC received 5,392 comments – 4,150 from patients, 702 from advocates and industry groups, 431 from caregivers, and 109 from clinicians.

The CDC also engaged in 106 conversations – 42 from patients, 21 from caregivers, and 43 from physicians.

Clearly, the CDC overemphasized direct, deep conversation with physicians over broad, public comments, as only 2% of the comments came from physicians but 66% of conversations were with physicians.

This may seem obvious. Of course, physicians are less likely to engage in public postings on government sites, and of course it makes sense to get deeper input from the physicians themselves – they are ultimately the decision-makers in prescribing opioids.

Despite the limited sample size, the data reveals something quite telling. Of all the conversations in which it was disclosed that opioids had a meaningful impact on patient care, roughly half said opioids “mostly helped”.

This is in stark contrast to the national narrative that poor prescribing practices – such as overprescribing – ushered in the opioid epidemic.

The conversations contradict the narrative.

And will likely guide a radical restructuring of the guidelines to be more favorable towards patients who receive opioids. While we generally agree with this sentiment, we cannot help but wonder if the CDC would have reached the same conclusion had it encouraged more public commentary from physicians.

Generally speaking, physicians have responded to the opioid epidemic by dramatically reducing the amount of opioids prescribed – some going so far as to tout opioid-free care management. So it would appear that most physicians agree that opioids are generally harmful.

But this is not what the conversations reveal. The private conversations reveal a more positive outlook for opioids, creating an interesting paradox between the public response and the private disclosures among physicians.

Which begs the question, why are private conversations with physicians contradicting the public perception touted among physicians?

Some may say physicians are being disingenuous publicly. Instead, we believe physicians are easily influenced.

Most physicians follow the prevailing narrative without much thought. Their understanding of the opioid epidemic was as influenced by the predominant narrative as the general public.

But physicians – being physicians – recontexualized the narrative into clinical terms, retrofitting the predominant belief into how they think clinically.

As a result, we saw a slew of clinical studies and thought leadership papers highlighting the clear and present danger of opioids. Just like we saw a slew of clinical studies and thought leadership papers highlighting the clear and present danger of poorly controlled pain two decades ago.

There is the data, and then there is the perception of the data. The studies we publish utilize data in ways that reflect the perceptions we hold – we are innately biased.

This explains there is disconnect between why we make decisions, and the justifications we claim for those decisions.

And why what physicians say publicly about opioids differs from what they say privately.

The implicit biases physician hold created the disparity between the intention of the 2016 guidelines and its implementation.

Now that we have the opportunity to revise the guidelines, the CDC would be remiss if it did not account for these biases.

Constructing guidelines that address more subtle, fundamental aspects of clinical decision-making – identifying paths of understanding for physicians.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Comments 0

  1. NORMAN CLEMENT says:
    5 years ago

    BLOOD MONEY: THE GREAT OPIOID CRISIS QUACKERY AND WHY

    https://youarewithinthenorms.com/2021/07/23/blood-money-the-great-opioid-crisis-quackery-and-why-medical-scientist-chronic-pain-patients-and-walmart-are-waging-war-against-the-dea-doj-from-extorting-billions-of-dollars-from-drug-manufacturer/

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • When Health Records Become Hostage: The Rise of Espionage in Healthcare Data Breaches

    When Health Records Become Hostage: The Rise of Espionage in Healthcare Data Breaches

    1 shares
    Share 0 Tweet 0
  • Abortion’s Precedent

    0 shares
    Share 0 Tweet 0
  • The Healthcare Jungle

    0 shares
    Share 0 Tweet 0
  • Vaping: A Tale of Two Crises

    0 shares
    Share 0 Tweet 0
  • Alternative Medications Might Help With Chronic Pain

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy